INCYs Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year…
108,675€
-1,54%
Echtzeit-Aktienkurs Incyte Corp
Bid:
Ask:
Nachrichten zur Incyte Corp Aktie
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Streets top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a…
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe…
Incyte: Multiple Drug Launches Bode Well For Future Growth
…
Aktie von Incyte büßt 1,52 Prozent ein (65,6412 €)
An der US-amerikanischen Börse notiert die Incyte-Aktie aktuell ein wenig leichter. Das Papier notiert zur Stunde bei 68,19 US-Dollar. Am…
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally.…
Incyte reports positive Phase 3 data for Zynyz for lung cancer
…
Incytes Late-stage NSCLC Study Meets Primary and Secondary Goals
INCYs phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer,…